Arrowhead Pharmaceuticals, Inc. (ARWR)
Nasdaq: ARWR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 1998
Filings
267 filings since 2017 beside 379 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-Q
Quarterly report for the quarter ending Dec 31, 2026Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Feb 9, 2027
10-K
Annual report for the fiscal year ending Sep 30, 2027Large accelerated filers have 60 days after the fiscal year ends.
by Nov 29, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Jan 27, 2026.
Filings a yearinsider forms included
71615250698810062
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 7 times in the last 36 months, the newest Jun 16, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Dec 5, 2023.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 4, 2026
8-K items 1.01, 2.03
Major agreement signed; New debt or obligation taken on · Current report
Jan 12, 2026
8-K items 1.01, 2.03, 9.01
Major agreement signed; New debt or obligation taken on · Current report
Jan 9, 2026
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Jan 7, 2026
Jan 6, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
40 of 267 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.